Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension
复制标题
DOI：
10.1185/030079908x301848
复制
发表时间：
2008-05-01
影响因子：
2.3
通讯作者：
Hollander, David A.
中科院分区：
文献类型：
--
作者：
Day, Douglas G.;Hollander, David A.
目的：评价普利莫尼定0.005.1%与布林唑胺1%辅助治疗0.005%拉坦前列素青光眼或高眼压的疗效和耐受性。方法：随机、单中心、研究者掩蔽、平行分组临床研究。在服用拉坦前列素的同时，10p>；=18 mm Hg的患者被随机分为布莫尼定纯品TID组(n=20)和布林唑胺TID组(n=20)，疗程3个月。分别在上午8点、10点和下午4点测量眼压(10P)。在拉坦前列素治疗的基础上，以及拉坦前列素和辅助治疗1个月和3个月后。结果：拉坦前列素的基础日均10p(+/-标准差，毫米汞)在两组间差异无统计学意义(普利莫尼定：19.6+/-2.94；布林唑胺：19.8+/-3.25；P=0.846)。纯溴莫尼定组和布林唑胺组3月日平均10P分别为16.3+/-2.63毫米汞柱和17.8+/-2.19毫米汞柱(p=0.028)。在上午10点，加用溴莫尼定纯净剂比布林唑胺有更大的10P降幅。(P<；0.001)和下午4点(P=0.050)和相当于上午8点降至布林唑胺的10P。(P=0.716)。布林唑胺滴眼液1个月时视力模糊，1、3个月时有苦味。结论：0.1%布林唑胺滴眼液与1%布林唑胺滴眼液相比，其10P显著低于布林唑胺1%。两种辅助疗法的耐受性都很好。这项研究的局限性包括使用单一地点和样本量。需要更多的研究来进一步评估这些药物作为前列腺素类似物的辅助治疗。
Objective: To evaluate the efficacy and tolerability of brimonidine purite 0.1% in comparison to brinzolamide 1% when used as adjunctive therapy to latanoprost 0.005% in patients with glaucoma or ocular hypertension.Methods: Randomized, single-center, investigator-masked, parallel-group clinical study. Patients with 10P >= 18 mmHg while on once-daily latanoprost were randomized to adjunctive treatment with brimonidine purite TID (n = 20) or brinzolamide TID (n = 20) for 3 months. Intraocular pressure (10P) was measured at 8 a.m., 10 a.m., and 4 p.m. at latanoprost-treated baseline and after 1 and 3 months of latanoprost and adjunctive therapy. A patient questionnaire was administered to evaluate the tolerability of eye drop instillation.Results: Baseline mean diurnal 10P (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846). Mean diurnal 10P at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028). Adjunctive use of brimonidine purite provided greater 10P lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent 10P lowering to brinzolamide at 8 a.m. (p = 0.716). Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.Conclusion: Brimonidine purite 0.1% provided significantly lower 10P compared with brinzolamide 1% when used as adjunctive therapy to latanoprost. Both adjunctive therapies were well tolerated. Limitations of this study include the use of a single site and the sample size. Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.